Samsung Bioepis, a subsidiary of Samsung Epis (KRX:0126Z0), submitted a biologics license application to the U.S. FDA on Thursday, Oct. 29, for SB27, a biosimilar of Merck's Keytruda, or pembrolizumab, according to a Korea filing on Monday.
The biologics license application takes into account 18 cancer indications, including melanoma, lung cancer, and breast cancer, the filing said.
The submission comes after a Phase Three trial involving 555 patients with metastatic non-squamous non-small cell lung cancer, which demonstrated equivalent efficacy and comparable safety between SB27 and Keytruda, it said.
Shares of Samsung Epis fell over 1% in recent trade.
Comments